Strong immunogenicity of a multicomponent peptide vaccine developed with the branched lysine oligopeptide method for human immunodeficiency virus infection

This publication has 26 references indexed in Scilit:

• Vaccine Protection of Chimpanzees Against Challenge with HIV-1-Infected Peripheral Blood Mononuclear Cells
  Science, 1992
• Safety and Immunogenicity of a Genetically Engineered Human Immunodeficiency Virus Vaccine
  The Journal of Infectious Diseases, 1991
• Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus.
  Proceedings of the National Academy of Sciences, 1991
• The Safety and Immunogenicity of a Human Immunodeficiency Virus Type 1 (HIV-1) Recombinant gp160 Candidate Vaccine in Humans
  Annals of Internal Medicine, 1991
• HGP-30, a synthetic analogue of human immunodeficiency virus (HIV) p17, is a target for cytotoxic lymphocytes in HIV-infected individuals.
  Proceedings of the National Academy of Sciences, 1990
• Immune response and epitope mapping of a candidate hiv‐1 p17 vaccine hgp30
  Journal of Clinical Laboratory Analysis, 1990
• Prospects for Prevention of and Early Intervention Against HIV
  JAMA, 1989
• Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.
  Proceedings of the National Academy of Sciences, 1988
• Second Conserved Domain of gp120 Is Important for HIV Infectivity and Antibody Neutralization
  Science, 1988
• Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide.
  Proceedings of the National Academy of Sciences, 1987